1. Home
  2. INVE vs ENTX Comparison

INVE vs ENTX Comparison

Compare INVE & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Identiv Inc.

INVE

Identiv Inc.

HOLD

Current Price

$5.15

Market Cap

119.1M

Sector

Technology

ML Signal

HOLD

ENTX

Entera Bio Ltd.

HOLD

Current Price

$1.31

Market Cap

62.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INVE
ENTX
Founded
1990
2010
Country
United States
Israel
Employees
N/A
N/A
Industry
Computer peripheral equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
119.1M
62.6M
IPO Year
1997
2015

Fundamental Metrics

Financial Performance
Metric
INVE
ENTX
Price
$5.15
$1.31
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$5.50
$9.00
AVG Volume (30 Days)
324.9K
124.9K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.25
Revenue
$60,219,000.00
$42,000.00
Revenue This Year
$22.10
N/A
Revenue Next Year
$20.74
N/A
P/E Ratio
N/A
$5.44
Revenue Growth
7.21
N/A
52 Week Low
$3.08
$0.91
52 Week High
$5.30
$3.22

Technical Indicators

Market Signals
Indicator
INVE
ENTX
Relative Strength Index (RSI) 72.19 55.67
Support Level $3.25 $1.12
Resistance Level N/A $1.38
Average True Range (ATR) 0.32 0.10
MACD 0.07 0.02
Stochastic Oscillator 90.03 76.67

Price Performance

Historical Comparison
INVE
ENTX

About INVE Identiv Inc.

Identiv Inc develops specialty radio-frequency identification (RFID) and Internet of Things It (IoT) solutions that address customers' challenges and create new opportunities for them through the digitization and enhanced connectivity to the IoT. It designs, produces, and sells RFID and Bluetooth Low Energy (BLE) enabled devices, RFID inlays, tags, and labels that can be applied or incorporated into physical objects, providing them with a digital identity and the ability for customers to track, monitor, authenticate, and engage with consumers. Its IoT Business segment develops, manufactures, and supplies specialty IoT solutions tailored for the healthcare, logistics, smart packaging industries and other high-value end markets.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

Share on Social Networks: